Literature DB >> 12062267

Angiographic evaluation of the luminal changes in the radial artery graft in coronary artery bypass surgery: a concern over the long-term patency.

Masahiro Ikeda1, Hirokazu Ohashi, Yasushi Tsutsumi, Katsuaki Hige, Takahiro Kawai, Masateru Ohnaka.   

Abstract

OBJECTIVE: The radial artery graft (RA) still involves two unsolved problems, namely, vasospasm and intimal hyperplasia, although satisfactory early and mid-term outcomes have been obtained recently.
METHODS: Two hundred patients underwent coronary artery bypass surgery with RA between October,1996 and December,2000. We made a comparison of the luminal diameters at early and mid-term periods in 23 patients who underwent mid-term angiographies after a mean follow-up of 27 months. The proximal anastomoses of the RA were the ascending aorta in these patients. The G/N ratio was determined as a ratio of the luminal diameter of the graft to that of the revascularized coronary artery so as to evaluate the luminal discrepancy between the graft and the native artery.
RESULTS: In the 122 patients who underwent angiographies about one month after the operation, the patency rate was 99% (144 of 145) in the RA, 97% (139 of 143) in the left internal thoracic artery graft (LITA), 96% (75 of 78) in the saphenous vein graft (SV). In the 23 patients who underwent mid-term angiographies, the patency rate was 91% (24 of 26) in the RA, 100% (23 of 23) in the LITA, and 83% (20 of 24) in the SV. The luminal diameters of the RA and LITA significantly increased from 2.15 to 2.52 mm, and from 1.75 to 1.97 mm, respectively. The luminal change from 3.78 to 3.33 mm in the SV was not significant. The G/N ratios changed from 1.10 to 1.31, from 1.01 to 1.13, and from 2.05 to 1.86 in the RA, LITA, and SV, respectively. The change of the RA alone was statistically significant.
CONCLUSIONS: The angiographic early patency rate was almost the same in three kinds of graft material, but the mid-term patency rate of the RA was between those of the LITA and SV. The mid-term luminal dilatation of the RA could involve two conflicting characteristics, namely, a good intimal function and a propensity to increase in the luminal discrepancy. Therefore, a further observation is required to evaluate whether the clinical outcome of the RA could remain as good as that of the LITA in the long-term period.

Entities:  

Mesh:

Year:  2002        PMID: 12062267     DOI: 10.1016/s1010-7940(02)00077-5

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Superficial palmar arch: an arterial diameter study.

Authors:  Valéria Paula Sassoli Fazan; Celso Teixeira Borges; Jefferson Hilário Da Silva; Abadio Gonçalves Caetano; Omar Andrade Rodrigues Filho
Journal:  J Anat       Date:  2004-04       Impact factor: 2.610

Review 2.  Radial artery graft vs. saphenous vein graft for coronary artery bypass surgery : which conduit offers better efficacy?

Authors:  H Zhang; Z W Wang; H B Wu; X P Hu; Z Zhou; P Xu
Journal:  Herz       Date:  2013-06-21       Impact factor: 1.443

Review 3.  Saphenous vein graft vs. radial artery graft searching for the best second coronary artery bypass graft.

Authors:  Hilal Ali Al-Sabti; Adil Al Kindi; Khalid Al-Rasadi; Yajnavalka Banerjee; Khamis Al-Hashmi; Ali Al-Hinai
Journal:  J Saudi Heart Assoc       Date:  2013-10

4.  Short- and long-term results of radial artery and saphenous vein grafts in the right coronary system: a propensity-matched study.

Authors:  Shohei Yoshida; Satoshi Numata; Yasushi Tsutsumi; Osamu Monta; Sachiko Yamazaki; Hiroyuki Seo; Takaaki Samura; Hirokazu Ohashi
Journal:  Surg Today       Date:  2016-08-09       Impact factor: 2.549

5.  Assessing the Long-term Patency and Clinical Outcomes of Venous and Arterial Grafts Used in Coronary Artery Bypass Grafting: A Meta-analysis.

Authors:  Abdul Waheed; Emily Klosterman; Joseph Lee; Ankita Mishra; Vijay Narasimha; Faiz Tuma; Faran Bokhari; Furqan Haq; Subhasis Misra
Journal:  Cureus       Date:  2019-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.